The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...
MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...
Over 11,000 liver transplants were performed last year in the US, while thousands more patients remained in limbo.
MedPage Today on MSN
Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial
Approved targeted drugs for HER2 -mutant NSCLC include trastuzumab deruxtecan (T-DXd, Enhertu) -- which is highly effective ...
MedPage Today on MSN
Could This Be the First Disease-Modifying Drug in Bronchiectasis?
C HICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...
Pharmaceutical Technology on MSN
GSK targets Syndivia’s prostate cancer ADC in £268m buy
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...
Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as an oral treatment option for idiopathic pulmonary ...
Boehringer Ingelheim’s Jascayd approved in China to treat idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, October 23, 2025, 12:00 Hrs [IST] Boehringer Ingelheim’s ...
Boehringer Ingelheim hired Ryan Donnelly as senior associate director of government affairs and public policy. Greg ...
Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
Privately-held German drugmaker Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by China’s National Medical ...
CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback